Semaglutide for PCOS: What the Research Actually Shows
Semaglutide is not FDA-approved for PCOS. Two small Chinese trials found adding it to metformin improved weight loss and menstrual-cycle recovery versus metformin alone; one reported a 35% vs. 15% natural pregnancy rate. Prescribing among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Semaglutide is not FDA-approved for PCOS, and the research on it for this condition is early. In two small, short, open-label randomized trials from China, adding semaglutide to metformin produced more weight loss, greater improvement in insulin resistance, and higher menstrual-cycle recovery rates than metformin alone in overweight or obese women with PCOS [3, 4]. One of the two trials also found a higher natural pregnancy rate afterward [3]. A 2026 scoping review included 25 studies, but only 5 were full papers — the rest were conference abstracts or structured summaries [5].
Real-world prescribing has already moved fast. Among women with a PCOS diagnosis, semaglutide or tirzepatide prescribing rose from 2.4% in 2021 to 17.6% in 2025, a 637.5% relative increase [1]. But the same analysis found 97.8% of GLP-1-treated women with PCOS also had obesity and/or type 2 diabetes, so much of that prescribing likely targets metabolic conditions rather than PCOS itself [1].
Is semaglutide approved for PCOS?
No. GLP-1 receptor agonists are not approved specifically for PCOS, and semaglutide and tirzepatide carry FDA-approved indications for obesity and/or type 2 diabetes [1]. Any prescription written with PCOS symptoms in mind falls outside those approved uses.
PCOS is common. One source puts it at 6–10% of reproductive-aged women [1]; a trial paper cites prevalence of 11–13% [3]. The condition is defined by hyperandrogenism, chronic oligo-ovulation, and polycystic ovarian morphology, and it frequently comes with obesity, insulin resistance, and dyslipidemia [3].
How common is off-label use already?
A Truveta analysis of records from January 2021 to September 2025 found 1,738,008 women received a semaglutide or tirzepatide prescription, and 90,210 of them (5.2%) had a PCOS diagnosis [1]. Among women prescribed these drugs, the share with PCOS rose from 4.6% in 2021 to 5.7% in 2025, a 23.9% relative increase [1].
Going the other direction: among women with PCOS who had a medical encounter in a given year, semaglutide or tirzepatide prescribing climbed from 2.4% in 2021 to 17.6% in 2025 [1]. Within that group, tirzepatide use rose from 0.7% in 2022 to 2.8% in 2025, while semaglutide fell from 4.2% to 2.1% [1].
The authors note the rise may reflect the high prevalence of metabolic comorbidities in PCOS rather than prescribing for PCOS itself: 97.8% of GLP-1-treated women with PCOS also had obesity and/or type 2 diabetes, versus 88.2% of GLP-1-treated women without PCOS [1]. The analysis identified PCOS by a single diagnosis code, did not account for metformin, oral contraceptives, or anti-androgen therapies, and is preliminary research that has not been peer reviewed [1].
Why would semaglutide help PCOS symptoms?
The main theory runs through insulin. Elevated insulin levels drive excess androgen production, which contributes to irregular ovulation and other PCOS symptoms [1]. Weight matters too: obesity affects roughly 20–80% of women with PCOS [3], and overweight or obesity prevalence in PCOS exceeds 40% [4]. A weight loss of 5–10% can significantly improve PCOS features and long-term outcomes [3], and losing 5–15% within six months has been linked to better ovulation, more regular cycles, reduced hirsutism, improved insulin sensitivity, and lower serum androgens [4].
The problem is getting that weight off and keeping it off. First-line lifestyle interventions often produce unsatisfactory and unsustainable results in clinical practice [3], and metformin improves insulin resistance and ovulation but has limited effect on weight in people with obesity [3]. That is the question the two randomized trials set out to answer: whether adding semaglutide to metformin improves on metformin alone [3, 4].
There may also be effects beyond weight. Early laboratory studies in mice suggest GLP-1 receptor agonists may reduce inflammation in the ovaries and help lower androgen levels [1]. Preclinical data also suggest possible stimulation of luteinizing hormone secretion and effects on ovarian morphology and endometrial receptivity that appear independent of weight loss [8]. These are lab findings, not confirmed human outcomes.
What did the randomized trials find?
Two randomized trials have tested semaglutide added to metformin in overweight or obese women with PCOS. Both were open-label, conducted in China, and short.
| Trial 1 (Reproductive Biology and Endocrinology, 2025) [3] | Trial 2 (Metabolism and Target Organ Damage, published 16 March 2026) [4] | |
|---|---|---|
| Participants | 100 overweight/obese women, Rotterdam criteria | 64 women with PCOS-related infertility, BMI ≥ 24 kg/m² |
| Comparison | Metformin alone vs. metformin + semaglutide | Metformin alone vs. metformin + semaglutide |
| Duration | 16 weeks (then metformin-only to week 40) | 12 weeks, then 8-week washout |
| Completion | 80 of 100 (80%) | Not reported |
| Weight loss | 6.09 ± 3.34 kg (combination) vs. 2.25 ± 4.27 kg (metformin alone) | Greater reductions in BMI, weight, waist and hip circumference, body fat % (P < 0.05) |
| Menstrual cycles | Higher recovery rate with combination | 86.87% vs. 60.00% restored cycles (P = 0.038) |
| Pregnancy | 35% vs. 15% natural pregnancy rate, weeks 16–40 (P < 0.05) | Not reported as an endpoint |
In Trial 1, the combination group had greater reductions in body weight, BMI, and waist-to-hip ratio (all P < 0.01), plus greater improvement in testosterone, the Chinese visceral adiposity index, and C-reactive protein [3]. From weeks 16 to 40, after all participants switched to metformin alone, the group that had received the combination achieved a natural pregnancy rate of 35% versus 15% (P < 0.05) [3]. The trial was registered as ChiCTR2400090908 on 2024-10-15 [3].
In Trial 2, both groups did lifestyle modification; the semaglutide-intensified group showed significant reductions in luteinizing hormone, androgens, and the LH/FSH ratio, plus greater reductions in fasting plasma glucose, fasting insulin, and HOMA-IR (P < 0.05) [4]. There was no significant difference in total cholesterol, triglycerides, or LDL cholesterol, and psychological distress was not worsened in the semaglutide group [4].
A meta-analysis published in Gynecological Endocrinology examined semaglutide’s effects on BMI and blood lipid levels in PCOS patients [2].
How strong is the evidence, really?
Thin. The 2026 scoping review searched SciSpace (411 records), Google Scholar (98), and PubMed (37), finding 546 total; registry screening of ClinicalTrials.gov and WHO ICTRP added 0 records [5]. After removing 190 duplicates, 356 records were screened and 328 excluded; 28 were assessed, and 25 were included in the qualitative synthesis [5]. Of those 25, only 5 were full papers — 23 were conference abstracts or structured summaries, and 2 records could not be source-verified [5].
The two main randomized trials enrolled 64 and 100 participants and ran 12 and 16 weeks [3, 4]. Both were open-label, both enrolled only overweight or obese participants, and both were conducted in China [3, 4]. Neither tested semaglutide head-to-head against metformin — both tested it as an add-on [3, 4]. Findings from these trials should not be generalized to women with PCOS at a normal weight, since no normal-weight participants were enrolled [3, 4].
Semaglutide vs. metformin for PCOS: which is better?
There is no completed head-to-head comparison. Metformin is the standard treatment for insulin resistance in PCOS, and combined oral contraceptives are standard for cycle irregularity and androgen-related symptoms [1]. Metformin has documented benefits for insulin resistance, ovulation, and reproductive outcomes, but it is weak for weight loss [3].
What the trials support is narrower: adding semaglutide to metformin beat metformin alone on weight, glucose, insulin resistance, and menstrual cyclicity in both trials [3, 4]. A head-to-head trial of semaglutide versus metformin in PCOS is registered on ClinicalTrials.gov as NCT05646199, but no completed head-to-head results have been published [6].
Will semaglutide make my periods regular?
The trial evidence points that way, with caveats. In the 12-week trial, 86.87% of the combination group had restored menstrual cycles versus 60.00% of the metformin-only group (P = 0.038) [4]. The 16-week trial also reported higher rates of menstrual cycle recovery with the combination [3]. Broader literature summaries associate GLP-1 use in PCOS with improved menstrual regularity and decreased ovarian cysts [1]. These results come from overweight or obese women in two small, open-label trials, not from large blinded studies [3, 4].
Androgen symptoms are less clear. One trial reported reductions in LH and androgens [4]; the other reported improvement in testosterone [3]. Hirsutism improvement is linked to 5–15% weight loss in general, but it has not been demonstrated as a semaglutide trial endpoint [4].
Can semaglutide help me get pregnant with PCOS?
Possibly, but it is not a fertility treatment. No GLP-1 medication has an FDA approval related to fertility [7, 8]. PCOS is the primary cause of anovulatory infertility [4], and weight is a major factor: each BMI point above 29 decreases female fertility by about 5% [7], fertility rates drop 8% in overweight women and 18% in women with obesity, and BMI ≥ 24 correlates with impaired reproductive capacity [4].
The one pregnancy figure comes from Trial 1: after 16 weeks of treatment, all participants switched to metformin alone, and from weeks 16 to 40 the former combination group had a 35% natural pregnancy rate versus 15% in the metformin-only group (P < 0.05) [3]. That is a single open-label result from one trial, not proof that semaglutide restores fertility reliably [3].
Does semaglutide affect birth control pills?
It can. GLP-1s slow gastric emptying, and oral contraceptive absorption may be reduced as a result — the risk is highest during dose titration weeks [7]. One OB/GYN advises using a backup barrier method, such as condoms or a diaphragm, during titration, or switching to a contraceptive that is not affected: an IUD, the Nexplanon implant, or a vaginal ring [7].
The absorption effect has been specifically demonstrated with tirzepatide: the prescribing information for Mounjaro and Zepbound advises a non-oral contraceptive or an added barrier method for 4 weeks after starting the drug and for 4 weeks after each dose increase [8].
What if I get pregnant while taking it?
Clinicians quoted in the cited coverage say a person who becomes pregnant while on a GLP-1 should stop the medication and contact their OB/GYN [7, 8]. Animal studies have shown possible fetal harm, including skeletal abnormalities and reduced fetal growth [8]. Human data are limited but somewhat reassuring: a prospective cohort study of 168 patients exposed to a GLP-1 in the first trimester found no increased risk of major birth defects or pregnancy loss, though the sample was small and the researchers called for more study [7, 8].
For anyone planning pregnancy, experts advise stopping GLP-1s before trying to conceive — one source says 1 to 2 months depending on the product [8], and one reproductive endocrinologist recommends 1 to 3 months depending on the drug’s pharmacokinetics [8].
What happens when you stop taking it?
Weight regain after stopping weight-management medication is a documented concern. It has been examined in a BMJ systematic review and meta-analysis of weight regain after stopping medication, and in the STEP 1 trial extension that followed semaglutide users after withdrawal [10, 11].
Neither PCOS trial reported long-term post-stopping outcomes: Trial 2 included an 8-week washout after 12 weeks of treatment [4], and Trial 1 moved all participants to metformin alone from week 16 to week 40 [3].
What should I ask my clinician?
Four questions worth raising:
- Which approved indication — obesity or type 2 diabetes — would a prescription fall under, since PCOS alone is not one [1]?
- How would it fit alongside current standard treatments such as metformin, combined oral contraceptives, or anti-androgens [1]?
- What is the contraception plan before starting, including non-oral options like an IUD, implant, or ring [7, 8]?
- If pregnancy is a goal, when should the medication be stopped beforehand — expert guidance ranges from 1 to 3 months depending on the product [8]?
Sources
- Truveta. Rising use of GLP-1 medications among women with PCOS. December 9, 2025.
- Taylor & Francis Online. Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.
- Reproductive Biology and Endocrinology. Effects of combined metformin and semaglutide therapy in overweight/obese women with polycystic ovary syndrome: a randomized, controlled, open-label clinical trial.
- OAE Publishing. Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial.
- MDPI. Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review.
- ClinicalTrials.gov. Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS). Study NCT05646199.
- Cleveland Clinic. ‘Ozempic Babies’: How GLP-1 Agonists Affect Fertility. March 10, 2025.
- Endocrinology Advisor. GLP-1s and Fertility.
- Novo Nordisk. Wegovy prescribing information.
- PubMed. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- The BMJ. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. January 7, 2026.
Frequently asked questions
Is Ozempic or Wegovy FDA-approved for PCOS?
No. GLP-1 receptor agonists are not approved specifically for PCOS; semaglutide products carry FDA-approved indications for obesity and/or type 2 diabetes. Any use aimed at PCOS symptoms is off-label, and 97.8% of GLP-1-treated women with PCOS in one analysis also had obesity and/or type 2 diabetes.
How much weight do women with PCOS lose on semaglutide plus metformin?
In a 16-week open-label trial of 100 overweight or obese women with PCOS, the metformin-plus-semaglutide group lost an average of 6.09 ± 3.34 kg, versus 2.25 ± 4.27 kg with metformin alone. The combination also produced greater reductions in BMI and waist-to-hip ratio (all P < 0.01).
Will semaglutide make my periods regular again?
In a 12-week trial, 86.87% of women taking semaglutide added to metformin had restored menstrual cycles versus 60.00% on metformin alone (P = 0.038). A second 16-week trial also reported higher menstrual recovery rates with the combination. Both trials were small, open-label, and limited to overweight or obese participants [3, 4].
Semaglutide vs. metformin for PCOS — which is better?
No completed head-to-head trial exists. Both randomized trials tested semaglutide added to metformin, and the combination beat metformin alone on weight, glucose, insulin resistance, and menstrual cyclicity [3, 4]. A head-to-head trial, NCT05646199, is registered on ClinicalTrials.gov, but no completed head-to-head results have been published.
Can semaglutide help me get pregnant with PCOS?
It is not a fertility treatment, and no GLP-1 has an FDA approval related to fertility [7, 8]. One trial reported a 35% natural pregnancy rate versus 15% in the follow-up period after combination therapy, once everyone had switched to metformin alone. That is a single small, open-label result, not proof of reliable fertility restoration.
Does semaglutide make birth control pills less effective?
GLP-1s slow gastric emptying, and oral contraceptive absorption may be reduced, with the highest risk during dose-titration weeks. A backup barrier method is advised during titration, or a switch to an IUD, implant, or vaginal ring. The effect has been specifically demonstrated with tirzepatide, whose labeling advises added protection for 4 weeks after starting and after each dose increase.
How long before trying to conceive should I stop semaglutide?
Expert guidance calls for stopping GLP-1s before conception — one source says 1 to 2 months depending on the product, and one reproductive endocrinologist recommends 1 to 3 months depending on the drug's pharmacokinetics. Animal studies show possible fetal harm, including skeletal abnormalities and reduced fetal growth.
Is it safe if I get pregnant while taking semaglutide?
Clinicians say a person who becomes pregnant on a GLP-1 should stop the medication and contact their OB/GYN right away [7, 8]. A prospective cohort study of 168 patients exposed in the first trimester found no increased risk of major birth defects or pregnancy loss, but the sample was small and more research is needed [7, 8]. Animal studies have shown possible fetal harm.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.